LEO1 is regulated by PRL-3 and mediates its oncogenic properties in acute myelogenous leukemia

Cancer Research

Volumn 74, Issue 11, 2014, Pages 3043-3053

  Chong, Phyllis S Y ^a   Zhou, Jianbiao ^a   Cheong, Lip Lee ^b   Liu, Shaw Cheng ^a   Qian, Jingru ^c   Guo, Tiannan ^c   Sze, Siu Kwan ^c   Zeng, Qi ^d   Chng, Wee Joo ^a,b,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^e NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE; HISTONE DEMETHYLASE; HISTONE H3; HISTONE H3 LYSINE 9; JMJD2C HISTONE DEMETHYLASE; LEO1 PROTEIN; PRL 3 PROTEIN; RNA POLYMERASE II; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX4; UNCLASSIFIED DRUG; HISTONE; KDM4C PROTEIN, HUMAN; LEO1 PROTEIN, HUMAN; PROTEIN TYROSINE PHOSPHATASE; PTP4A3 PROTEIN, HUMAN; SOX2 PROTEIN, HUMAN; SOX4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; COLONY FORMING CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LEUKEMIA CELL; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROMOTER REGION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEK293 CELLS; HISTONE DEMETHYLASES; HISTONES; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM PROTEINS; ONCOGENES; PROMOTER REGIONS, GENETIC; PROTEIN TYROSINE PHOSPHATASES; SOXB1 TRANSCRIPTION FACTORS; SOXC TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84902181018     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2321     Document Type: Article

References (32)

1. Zeng Q, Si X, Horstmann H, Xu Y, Hong W, Pallen CJ. Prenylationdependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J Biol Chem 2000;275:21444-52.
2. Al-Aidaroos AQ, Zeng Q. PRL-3 phosphatase and cancer metastasis. J Cell Biochem 2010;111:1087-98.
3. Kato H, Semba S, Miskad UA, Seo Y, Kasuga M, Yokozaki H. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: A predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 2004;10: 7318-28.
4. Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, et al. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res 2005;11:6835-9.
5. Radke I, Gotte M, Kersting C, Mattsson B, Kiesel L, Wulfing P. Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer 2006;95:347-54.
6. Chu ZH, Liu L, Zheng CX, Lai W, Li SF, Wu H, et al. Proteomic analysis identifies translationally controlled tumor protein as a mediator of phosphatase of regenerating liver-3-promoted proliferation, migration and invasion in human colon cancer cells. Chin Med J (Engl) 2011; 124:3778-85.
7. Jiang Y, Liu XQ, Rajput A, Geng L, Ongchin M, Zeng Q, et al. Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis. Cancer Res 2011;71:234-44.
8. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, Croix BS, et al. A phosphatase associated with metastasis of colorectal cancer. Science 2001;294:1343-6.
9. Bardelli A, Saha S, Sager JA, RomansKE, Xin B, Markowitz SD, et al.PRL- 3 expression in metastatic cancers. Clin Cancer Res 2003;9:5607-15.
10. Wang H, Vardy LA, Tan CP, Loo JM, Guo K, Li J, et al. PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell 2010;18:52-62.
11. Bessette DC, Qiu D, Pallen CJ. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev 2008;27:231-52.
12. Guo K, Li J, Tang JP, Tan CBP, Hong CW, Al-Aidaroos AQ, et al. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med 2011;3:99ra85.
13. Zhou J, Bi C, Chng WJ, Cheong LL, Liu SC, Mahara S, et al. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS ONE 2011;6: e19798.
14. Beekman R, Valkhof M, Erkeland SJ, Taskesen E, Rockova V, Peeters JK, et al. Retroviral integration mutagenesis in mice and comparative analysis in human AML identify reduced PTP4A3 expression as a prognostic indicator. PLoS ONE 2011;6:e26537.
15. Muntean AG, Tan J, Sitwala K, Huang Y, Bronstein J, Connelly JA, et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 2010;17:609-21.
16. Liu Y, Zheng P, Liu Y, Ji T, Liu X, Yao S, et al. An epigenetic role for PRL- 3 as a regulator of H3K9 methylation in colorectal cancer. Gut 2013;62:571-81.
17. Shin S, Janknecht R. Diversity within the JMJD2 histone demethylase family. Biochem Biophys Res Commun 2007;353:973-7.
18. Semba S, Mizuuchi E, Yokozaki H. Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma. Cancer Sci 2010; 101:2254-61.
19. Zheng P, Liu YX, Chen L, Liu XH, Xiao ZQ, Zhao L, et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 2010;9:4897-905.
20. Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, et al. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 2003;63:2716-22.
21. Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, et al. Overexpression and involvement in migration by the metastasisassociated phosphatase PRL-3 in human myeloma cells. Blood 2008;111:806-15.
22. Fiordalisi JJ, Keller PJ, Cox AD. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res 2006;66:3153-61.
23. Squazzo SL, Costa PJ, Lindstrom DL, Kumer KE, Simic R, Jennings JL, et al. The Paf1 complex physically and functionally associates with transcription elongation factors in vivo. EMBO J 2002;21: 1764-74.
24. Chaudhary K, Deb S, Moniaux N, Ponnusamy MP, Batra SK. Human RNA polymerase II-associated factor complex: dysregulation in cancer. Oncogene 2007;26:7499-507.
25. Wang P, Bowl MR, Bender S, Peng J, Farber L, Chen J, et al. Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice. Mol Cell Biol 2008;28:2930-40.
26. Takahashi A, Tsutsumi R, Kikuchi I, Obuse C, Saito Y, Seidi A, et al. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell 2011;43:45-56.
27. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003;3:89-101.
28. Mosimann C, Hausmann G, Basler K. Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with betacatenin/Armadillo. Cell 2006;125:327-41.
29. Sandoval S, Kraus C, Cho EC, Cho M, Bies J, Manara E, et al. Sox4 cooperates with CREB in myeloid transformation. Blood 2012;120: 155-65.
30. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, et al. The putative oncogene GASC1 demethylates tri- And dimethylated lysine 9 on histone H3. Nature 2006;442:307-11.
31. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011;21:381-95.
32. Fullgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene 2011;30:3391-403.